Drug Trial Radar · NCT00671307
Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels
Last checked: Nov 20, 2026Latest source record: Sep 29, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Planned (sponsor's estimate)
Start
Mar 2008
Primary completion
Mar 2010
Study completion May 2010
Sponsor
- Lead sponsor
- Critical Biologics CorporationIndustry
- Sponsor type
- Industry
- First posted
- May 5, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the pharmacokinetics and safety of an infusion of a single dose of recombinant plasma gelsolin (rhu-pGelsolin) when given to patients admitted to the Intensive Care Unit with documented low levels of natural gelsolin. It is believed that this drug will raise the gelsolin levels in these patients and decrease the probability that they will develop complications from their underlying disease such as organ system failure or death.
Conditions
- Low Gelsolin
- Trauma
- Infection
- Burns
Interventions
rhu-pGelsolinDrug
IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
PlaceboDrug
Vehicle control given as IV infusion over 1 hour
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics of plasma gelsolinTime frame: 72 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Queen Mary Hospital; University of Hong Kong
Hong Kong, SAR, Hong Kong
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.